(Q33709704)

28 July 2017

Predictors of switching antipsychotic medications in the treatment of schizophrenia (English)

1 reference

28 July 2017

0 references

3

Haya Ascher-Svanum

1 reference

28 July 2017

Allen W Nyhuis

1

1 reference

28 July 2017

Douglas E Faries

series ordinal

2

1 reference

28 July 2017

Virginia L Stauffer

series ordinal

4

1 reference

28 July 2017

Bruce J Kinon

series ordinal

5

1 reference

28 July 2017

language of work or name

1 reference

28 September 2010

1 reference

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

75

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-10-75

28 July 2017

0 references

cites work

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Adverse effects of antipsychotics as outcome measures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

21 June 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Switching antipsychotics: an updated review with a focus on quetiapine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Predictors of antipsychotic medication change

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Relapse in schizophrenia: costs, clinical outcomes and quality of life

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Gender differences in characteristics and service use of public mental health patients with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

A critical review of akathisia, and its possible association with suicidal behaviour

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Mediators and moderators of treatment effects in randomized clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Cost of relapse in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

A rating scale for extrapyramidal side effects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Suicide attempts associated with akathisia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The positive and negative syndrome scale (PANSS) for schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

A rating scale for drug-induced akathisia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Early Prediction of Antipsychotic Response in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-10-75

Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Compliance with antipsychotic drug treatment: influence of side effects.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2955631

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20920179

12 December 2020

inferred from PubMed ID database lookup

Atypical antipsychotics

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20920179

12 December 2020

inferred from PubMed ID database lookup

Early prediction of antipsychotic nonresponse among patients with schizophrenia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20920179

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/1471-244X-10-75

1 reference

Dimensions Publication ID

28 July 2017

1001193745

0 references

Fatcat ID

release_65bhrh3ngbh6xlasiyqtw7whfq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/65bhrh3ngbh6xlasiyqtw7whfq

24 November 2022

mapped directly with Wikidata item

PMCID

2955631

1 reference

28 July 2017

1 reference